<DOC>
	<DOC>NCT00469781</DOC>
	<brief_summary>The objective of this study is to determine if twice-daily dosing of prednisolone (Pred Forte) is as effective as four-times-daily dosing of prednisolone for the prevention of retinal thickening and cystoid macular edema (CME) when either regimen is used concomitantly with twice-daily bromfenac.</brief_summary>
	<brief_title>Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>· Male or female &gt; 18 years of age scheduled to undergo cataract surgery Must be in good general health. Patients with systemic diseases will be enrolled only if there are no ocular manifestations of their disease (ie diabetics with normal retinal exams) Expected visual outcome of 20/25 or better. Ability to provide informed consent and likely to complete all study visits · Known contraindication to any study medication or any of their components Uncontrolled systemic disease Required use of ocular medications other than the study medications during the study Abnormal preoperative OCTs Diabetic patients with a history of macular edema or diabetic retinopathy AMD, epiretinal membranes, retinal vein occlusion, or any preexisting macular disease Only one eye of each patient can be enrolled</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>